My passion for respiratory science started when I was at university. 我对呼吸系统如何与免疫和环境因素相互作用很感兴趣. 在正常肺部，这些触发因素具有保护作用，但在慢性肺病患者中，这些触发因素可能变得有害，并导致麻烦症状的增加. 很明显，这些患者有显著的治疗需求，而目前的治疗方法没有解决这些需求. As a Respiratory Pharmacologist, 因此，我最自豪的成就是研究两种治疗药物，这两种药物现在用于治疗哮喘和慢性阻塞性肺病. Although significant advances have been made, 澳门葡京赌博游戏不仅要研究慢性肺病的治疗，还要研究疾病的改变和治愈.
In September 2017, I joined AstraZeneca’s BioPharmaceuticals R&D group to head up the Respiratory, Inflammation & Autoimmunity research. I am based in Gothenburg, Sweden, at one of AstraZeneca’s three strategic research and development hubs, also home to the company’s early-stage respiratory research. In my role as Senior Vice President and Head of Early Respiratory, Inflammation and Autoimmunity (RIA), 我领导了慢性肺病的早期研究和开发，比如哮喘, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and chronic cough. We focus on three areas: lung epithelium, lung immunity and lung regeneration. 我真的很享受成为澳门葡京网赌游戏呼吸系统团队的一员，因为它让我有机会与鼓舞人心的科学家一起工作, 而且在一个拥有将科学推向治疗患者的新药所需的专业知识和能力的全球性组织内.
Although significant advances have been made, 澳门葡京赌博游戏不仅要研究慢性肺病的治疗，还要研究疾病的改变和治愈.
Alongside my role at AstraZeneca, 我是伦敦帝国学院呼吸药理学教授和呼吸药理学小组的负责人. My research is focused on the cellular and molecular mechanisms of asthma, COPD and chronic cough, with the aim of developing therapies for these conditions. 我喜欢帮助推动这里的研究工作，并成为培训下一代呼吸科学家的一部分.
2013年至2016年，我担任欧洲呼吸学会(ERS)的研究主任, and I have served on the editorial board of several scientific journals, including the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal and executive editor of Pharmacology and Therapeutics. I write extensively about respiratory illness and treatment, 我的许多论文被同行引用，并被其他出版物引用. I am also an elected Fellow of the British Pharmacological Society, European Respiratory Society and the Academy of Medical Sciences.
我的行业经验包括在Rhône-Poulenc Rorer(现为安万特制药公司)领导一个专注于呼吸系统疾病的团队. In 2010, I also started my own company with my colleague, Dr Mark Birrell, called IR Pharma, a Respiratory Pharmacology pre-clinical drug discovery organisation.
British Pharmacological Society AstraZeneca Women in Pharmacology Prize
Woman in Inflammation Science Award
Trabbuchi Award
Pfizer Awards for Science in the UK
Featured publications
Mechanistic link between diesel exhaust particles and respiratory reflexes.
Robinson RK, Birrell MA, Adcock JJ, Wortley MA, Dubuis ED, Chen S, McGilvery CM, Hu S, Shaffer MSP, Bonvini SJ, Maher SA, Mudway IS, Porter AE, Carlsten C, Tetley TD, Belvisi MG. J Allergy Clin Immunol. 2018 Mar;141(3):1074-1084.e9.
XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough.
Belvisi MG, Birrell MA, Wortley MA, Maher SA, Satia I, Badri H, Holt K, Round P, McGarvey L, Ford J, Smith JA. Am J Respir Crit Care Med. 2017 Nov 15;196(10):1255-1263.
Transient receptor potential cation channel, subfamily V, 成员4和气道感觉传入激活:三磷酸腺苷的作用.
Bonvini SJ, Birrell MA, Grace MS, Maher SA, Adcock JJ, Wortley MA, Dubuis E, Ching YM, Ford AP, Shala F, Miralpeix M, Tarrason G, Smith JA, Belvisi MG. J Allergy Clin Immunol. 2016 Jul;138(1):249-261.e12.
Neurophenotypes in Airway Diseases. Insights from Translational Cough Studies.
Belvisi MG, Birrell MA, Khalid S, Wortley MA, Dockry R, Coote J, Holt K, Dubuis E, Kelsall A, Maher SA, Bonvini S, Woodcock A, Smith JA. Am J Respir Crit Care Med. 2016 Jun 15;193(12):1364-72.
Therapeutic advances for treatment-resistant cough.
Belvisi MG. Lancet. 2015 Mar 28;385(9974):1160-2.
瞬时受体电位和泛联蛋白通道在香烟烟雾触发的ATP释放中的作用.
Baxter M, Eltom S, Dekkak B, Yew-Booth L, Dubuis ED, Maher SA, Belvisi MG, Birrell MA. Thorax. 2014 Dec;69(12):1080-9.
A role for sensory nerves in the late asthmatic response.
Raemdonck K, de Alba J, Birrell MA, Grace M, Maher SA, Irvin CG, Fozard JR, O'Byrne PM, Belvisi MG. Thorax. 2012 Jan;67(1):19-25.
Bronchodilator activity of bitter tastants in human tissue.
Belvisi MG, Dale N, Birrell MA, Canning BJ. Nat Med. 2011 Jul 7;17(7):776.
EP4 receptor as a new target for bronchodilator therapy.
Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, Belvisi MG. Thorax. 2011 Dec;66(12):1029-35.
TRPA1 agonists evoke coughing in guinea pig and human volunteers.
Birrell MA, Belvisi MG, Grace M, Sadofsky L, Faruqi S, Hele DJ, Maher SA, Freund-Michel V, Morice AH. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1042-7.
Ikappa-B激酶-2抑制剂阻断人气道平滑肌炎症和哮喘大鼠模型.
Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, Newton R, Haj-Yahia S, Pun KT, Watts CJ, Shaw RJ, Savage TJ, Belvisi MG. Am J Respir Crit Care Med. 2005 Oct 15;172(8):962-71
环来奈德，一种治疗哮喘的新型皮质类固醇的临床前概况.
Belvisi MG, Bundschuh DS, Stoeck M, Wicks S, Underwood S, Battram CH, Haddad el-B, Webber SE, Foster ML. J Pharmacol Exp Ther. 2005 Aug;314(2):568-74
解离糖皮质激素的治疗效益和体外分离转抑制与转激活活性的相关性.
Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML. J Immunol. 2001 Feb 1;166(3):1975-82.
缓激肽诱发气道感觉神经致敏:ace抑制剂咳嗽的一种机制.
Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ. Nat Med. 1996 Jul;2(7):814-7.
Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.
Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub MH, Barnes PJ. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1640-5.
Join AstraZeneca
and help us deliver life-changing medicines